Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition

manilatimes.net · 2026-08-26

NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with NeurocrineNxera to receive a US$10 million milestone payment upon IND Acceptance, as part of the overall milestone packageNxera retains development and commercialization rights to the M1 receptor agonist for all indications in JapanTokyo, Japan and Cambridge, UK, 26 August 2026 - Nxera Pharma Co., Ltd. ('Nxera” or 'the Company”; TSE 4565) announces that its partner Neurocrine Biosciences Inc. ('Neurocrine”) has received IND Acceptance from the U.S. Food and Drug Administration (FDA) for a Phase 2 study of NBI-1117567 ('NBI-’567”) for Alzheimer's cognition. Nxera will receive an IND Acceptance milestone payment of US$10 million from Neurocrine pursuant to the agreement. The milestone payment is expected to be recognised in full as revenue in Q3 FY2026. NBI-’567 is an investigational, orally administered, muscarinic M1 receptor preferring agonist discovered using Nxera’s proprietary NxWave™ drug discovery platform.

TickrTrends take: Neurocrine Biosciences' advancement of NBI-1117567 into Phase 2 testing represents progress in its Alzheimer's pipeline, which may eventually contribute to revenue diversification within the Healthcare sector. Given TickrTrends' current undervalued assessment of NBIX, investors monitoring the stock should track clinical development milestones and any updates on this program's efficacy and safety data, as successful trial progression could influence the company's long-term value proposition. The regulatory acceptance signals that the compound has met initial FDA requirements, though typical drug development timelines mean meaningful commercial impact remains years away.

Read the full story at manilatimes.net →